

10/031190

Practitioner's Docket No. YOU 2 0081**CHAPTER II**

## Preliminary Classification:

Proposed Class:

Subclass:

NOTE: "All applicants are requested to include a preliminary classification on newly filed patent applications. The preliminary classification, preferably class and subclass designations, should be identified in the upper right-hand corner of the letter of transmittal accompanying the application papers, for example 'Proposed Class 2, subclass 129.'" M.P.E.P., § 601, 7th ed.

**TRANSMITTAL LETTER  
TO THE UNITED STATES ELECTED OFFICE (EO/US)  
(ENTRY INTO U.S. NATIONAL PHASE UNDER CHAPTER II)**

INTERNATIONAL APPLICATION NO.	INTERNATIONAL FILING DATE	PRIORITY DATE CLAIMED
PCT/GB00/02674	11 July 2000 (11.07.2000)	13 July 1999 (13.07.1999)
TITLE OF INVENTION		
METHOD TO STUDY INSULIN ACTION		
APPLICANT(S)		
YEAMAN, Steve; SHEPHERD, Peter; ZORZANO, Antonio		

**Box PCT**  
**Assistant Commissioner for Patents**  
**Washington D.C. 20231**  
**ATTENTION: EO/US**

**CERTIFICATION UNDER 37 C.F.R. §§ 1.8(a) and 1.10\***

(When using Express Mail, the Express Mail label number is **mandatory**;  
Express Mail certification is optional.)

I hereby certify that, on the date shown below, this correspondence is being:

**MAILING**

☒ deposited with the United States Postal Service in an envelope addressed to the Assistant Commissioner for Patents, Washington, D.C. 20231

37 C.F.R. § 1.8(a)

37 C.F.R. § 1.10 \*

☐ with sufficient postage as first class mail.

☒ as "Express Mail Post Office to Addressee"

Mailing Label No. EL 852686921 US (mandatory)**TRANSMISSION**

☐ facsimile transmitted to the Patent and Trademark Office, (703) \_\_\_\_\_

Signature

Georgeen B. George

(type or print name of person certifying)

Date: 01/14/02

\* Only the date of filing (§ 1.6) will be the date used in a patent term adjustment calculation, although the date on any certificate of mailing or transmission under § 1.8 continues to be taken into account in determining timeliness. See § 1.703(f). Consider "Express Mail Post Office to Addressee" (§ 1.10) or facsimile transmission (§ 1.6(d)) for the reply to be accorded the earliest possible filing date for patent term adjustment calculations.

10/031190  
531 Rec'd PCT/P 14 JAN 2002

**NOTE:** To avoid abandonment of the application, the applicant shall furnish to the USPTO, not later than 20 months from the priority date: (1) a copy of the international application, unless it has been previously communicated by the International Bureau or unless it was originally filed in the USPTO; and (2) the basic national fee (see 37 C.F.R. § 1.492(a)). The 30-month time limit may not be extended. 37 C.F.R. § 1.495.

**WARNING:** Where the items are those which can be submitted to complete the entry of the international application into the national phase are subsequent to 30 months from the priority date the application is still considered to be in the international state and if mailing procedures are utilized to obtain a date the express mail procedure of 37 C.F.R. § 1.10 must be used (since international application papers are not covered by an ordinary certificate of mailing—See 37 C.F.R. § 1.8.

**NOTE:** Documents and fees must be clearly identified as a submission to enter the national state under 35 U.S.C. § 371 otherwise the submission will be considered as being made under 35 U.S.C. § 111. 37 C.F.R. § 1.494(f).

- I. Applicant herewith submits to the United States Elected Office (EO/US) the following items under 35 U.S.C. § 371:
- a. ☒ This express request to immediately begin national examination procedures (35 U.S.C. § 371(f)).
  - b. ☐ The U.S. National Fee (35 U.S.C. § 371(c)(1)) and other fees (37 C.F.R. § 1.492) as indicated below:

(Transmittal Letter to the United States Elected Office (EO/US) [13-18]—page 2 of 9)

100314 P0/031190

(Ref.88—10/01 Pub.605)

FORM 13-18

13-161

531 Rec'd PCT/PT 14 JAN 2002

## 2. Fees

CLAIMS FEE	(1) FOR	(2) NUMBER FILED	(3) NUMBER EXTRA	(4) RATE	(5) CALCULATIONS
<input checked="" type="checkbox"/> *	TOTAL CLAIMS	19 -20=	0	× \$18.00=	\$ 0
	INDEPENDENT CLAIMS	1 -3=	0	× \$84.00=	0
	MULTIPLE DEPENDENT CLAIM(S) (if applicable) 0 + \$280.00				
BASIC FEE**	<input type="checkbox"/> U.S. PTO WAS INTERNATIONAL PRELIMINARY EXAMINATION AUTHORITY Where an International preliminary examination fee as set forth in § 1.482 has been paid on the international application to the U.S. PTO: <input type="checkbox"/> and the international preliminary examination report states that the criteria of novelty, inventive step (non-obviousness) and industrial activity, as defined in PCT Article 33(1) to (4) have been satisfied for all the claims presented in the application entering the national stage (37 C.F.R. § 1.492(a)(4)) ..... \$100.00 <input type="checkbox"/> and the above requirements are not met (37 C.F.R. § 1.492(a)(1)) ..... \$710.00 <input checked="" type="checkbox"/> U.S. PTO WAS NOT INTERNATIONAL PRELIMINARY EXAMINATION AUTHORITY Where no international preliminary examination fee as set forth in § 1.482 has been paid to the U.S. PTO, and payment of an international search fee as set forth in § 1.445(a)(2) to the U.S. PTO: <input type="checkbox"/> has been paid (37 C.F.R. § 1.492(a)(2)) ..... \$740.00 <input type="checkbox"/> has not been paid (37 C.F.R. § 1.492(a)(3)) ..... \$1040.00 <input checked="" type="checkbox"/> where a search report on the international application has been prepared by the European Patent Office or the Japanese Patent Office (37 C.F.R. § 1.492(a)(5) ) ..... \$890.00				
	Total of above Calculations				= 890.00
SMALL ENTITY	Reduction by 1/2 for filing by small entity, if applicable. Assertion must be made. (note 37 C.F.R. § 1.27)				-
	Subtotal				890.00
	Total National Fee				\$ 890.00
	Fee for recording the enclosed assignment document \$40.00 (37 C.F.R. § 1.21(h)). (See Item 13 below). See attached "ASSIGNMENT COVER SHEET".				---
TOTAL	Total Fees enclosed				\$ 890.00

10/031190

531 Rec'd PCT/PT 14 JAN 2002

\*See attached Preliminary Amendment Reducing the Number of Claims.

- ☒ Attached is a ☒ check ☐ money order in the amount of \$ 890.00
- ☒ Authorization is hereby made to charge the amount of \$ 0
- ☒ to Deposit Account No. 06-0308
- ☐ to Credit card as shown on the attached credit card information authorization form PTO-2038.

**WARNING:** Credit card information should **not** be included on this form as it may become public.

- ☒ Charge any additional fees required by this paper or credit any overpayment in the manner authorized above.

A duplicate of this paper is attached.

**\*\*WARNING:** "To avoid abandonment of the application the applicant shall furnish to the United States Patent and Trademark Office not later than the expiration of 30 months from the priority date: \* \* \* (2) the basic national fee (see § 1.492(a)). The 30-month time limit may not be extended." 37 C.F.R. § 1.495(b).

**WARNING:** If the translation of the international application and/or the oath or declaration have not been submitted by the applicant within thirty (30) months from the priority date, such requirements may be met within a time period set by the Office. 37 C.F.R. § 1.495(b)(2). The payment of the surcharge set forth in § 1.492(e) is required as a condition for accepting the oath or declaration later than thirty (30) months after the priority date. The payment of the processing fee set forth in § 1.492(f) is required for acceptance of an English translation later than thirty (30) months after the priority date. Failure to comply with these requirements will result in abandonment of the application. The provisions of § 1.136 apply to the period which is set. Notice of Jan. 3, 1993, 1147 O.G. 29 to 40.

#### ☒ Assertion of Small Entity Status

#### ☐ Applicant hereby asserts status as a small entity under 37 C.F.R. § 1.27.

**NOTE:** 37 C.F.R. § 1.27(c) deals with the assertion of small entity status, whether by a written specific declaration thereof or by payment as a small entity of the basic filing fee or the fee for the entry into the national phase as states:

"(c) Assertion of small entity status. Any party (person, small business concern or nonprofit organization) should make a determination, pursuant to paragraph (f) of this section, of entitlement to be accorded small entity status based on the definitions set forth in paragraph (a) of this section, and must, in order to establish small entity status for the purpose of paying small entity fees, actually make an assertion of entitlement to small entity status, in the manner set forth in paragraphs (c)(1) or (c)(3) of this section, in the application or patent in which such small entity fees are to be paid.

(1) Assertion by writing. Small entity status may be established by a written assertion of entitlement to small entity status. A written assertion must:

(i) Be clearly identifiable;

(ii) Be signed (see paragraph (c)(2) of this section); and

(iii) Convey the concept of entitlement to small entity status, such as by stating that applicant is a small entity, or that small entity status is entitled to be asserted for the application or patent. While no specific words or wording are required to assert small entity status, the intent to assert small entity status must be clearly indicated in order to comply with the assertion requirement.

(2) Parties who can sign and file the written assertion. The written assertion can be signed by:

(i) One of the parties identified in §§ 1.33(b) (e.g., an attorney or agent registered with the Office), §§ 3.73(b) of this chapter notwithstanding, who can also file the written assertion;

(ii) At least one of the individuals identified as an inventor (even though a §§ 1.63 executed oath or declaration has not been submitted), notwithstanding §§ 1.33(b)(4), who can also file the written assertion pursuant to the exception under §§ 1.33(b) of this part; or

(iii) An assignee of an undivided part interest, notwithstanding §§ 1.33(b)(3) and 3.73(b) of this chapter, but the partial assignee cannot file the assertion without resort to a party identified under §§ 1.33(b) of this part.

(Transmittal Letter to the United States Elected Office (EO/US) [13-18]—page 4 of 9)

10031194 10/031190

531 Rec'd PCT/P 14 JAN 2002

(3) Assertion by payment of the small entity basic filing or basic national fee. The payment, by any party, of the exact amount of one of the small entity basic filing fees set forth in §§ 1.16(a), (f), (g), (h), or (k), or one of the small entity basic national fees set forth in §§ 1.492(a)(1), (a)(2), (a)(3), (a)(4), or (a)(5), will be treated as a written assertion of entitlement to small entity status even if the type of basic filing or basic national fee is inadvertently selected in error.

(i) If the Office accords small entity status based on payment of a small entity basic filing or basic national fee under paragraph (c)(3) of this section that is not applicable to that application, any balance of the small entity fee that is applicable to that application will be due along with the appropriate surcharge set forth in §§ 1.16(e), or §§ 1.16(f).

(ii) The payment of any small entity fee other than those set forth in paragraph (c)(3) of this section (whether in the exact fee amount or not) will not be treated as a written assertion of entitlement to small entity status and will not be sufficient to establish small entity status in an application or a patent."

3. ☒ A copy of the International application as filed (35 U.S.C. § 371(c)(2)):

NOTE: Section 1.495 (b) was amended to require that the basic national fee and a copy of the international application must be filed with the Office by 30 months from the priority date to avoid abandonment. "The International Bureau normally provides the copy of the international application to the Office in accordance with PCT Article 20. At the same time, the International Bureau notifies applicant of the communication to the Office. In accordance with PCT Rule 47.1, that notice shall be accepted by all designated offices as conclusive evidence that the communication has duly taken place. Thus, if the applicant desires to enter the national stage, the applicant normally need only check to be sure the notice from the International Bureau has been received and then pay the basic national fee by 30 months from the priority date." Notice of Jan. 7, 1993, 1147 O.G. 29 to 40, at 35-36. See item 14c below.

- a. ☒ is transmitted herewith.
- b. ☐ is not required, as the application was filed with the United States Receiving Office.
- c. ☐ has been transmitted
  - i. ☐ by the International Bureau.

Date of mailing of the application (from form PCT/1B/308):

- ii. ☐ by applicant on \_\_\_\_\_ (Date)

4. ☒ A translation of the International application into the English language (35 U.S.C. § 371(c)(2)):

- a. ☐ is transmitted herewith.
- b. ☒ is not required as the application was filed in English.
- c. ☐ was previously transmitted by applicant on \_\_\_\_\_ (Date)
- d. ☐ will follow.

5. ☒ Amendments to the claims of the International application under PCT Article 19 (35 U.S.C. § 371(c)(3)):

NOTE: The Notice of January 7, 1993 points out that 37 C.F.R. § 1.495(a) was amended to clarify the existing and continuing practice that PCT Article 19 amendments must be submitted by 30 months from the priority date and this deadline may not be extended. The Notice further advises that: "The failure to do so will not result in loss of the subject matter of the PCT Article 19 amendments. Applicant may submit that subject matter in a preliminary amendment filed under section 1.121. In many cases, filing an amendment under section 1.121 is preferable since grammatical or idiomatic errors may be corrected." 1147 O.G. 29-40, at 36.

- a. ☐ are transmitted herewith.  
b. ☐ have been transmitted  
i. ☐ by the International Bureau.

Date of mailing of the amendment (from form PCT/1B/308):  
\_\_\_\_\_

- ii. ☐ by applicant on \_\_\_\_\_. (Date)  
c. ☒ have not been transmitted as  
i. ☒ applicant chose not to make amendments under PCT Article 19.  
Date of mailing of Search Report (from form PCT/ISA/210):  
November 27, 2000.  
ii. ☐ the time limit for the submission of amendments has not yet expired. The amendments or a statement that amendments have not been made will be transmitted before the expiration of the time limit under PCT Rule 46.1.

6. ☒ A translation of the amendments to the claims under PCT Article 19 (38 U.S.C. § 371(c)(3)):

- a. ☐ is transmitted herewith.  
b. ☐ is not required as the amendments were made in the English language.  
c. ☒ has not been transmitted for reasons indicated at point 5(c) above.

7. ☒ A copy of the international examination report (PCT/IPEA/409)

- ☒ is transmitted herewith.  
☐ is not required as the application was filed with the United States Receiving Office.

8. ☐ Annex(es) to the international preliminary examination report

- a. ☐ is/are transmitted herewith.  
b. ☐ is/are not required as the application was filed with the United States Receiving Office.

9. ☐ A translation of the annexes to the international preliminary examination report

- a. ☐ is transmitted herewith.  
b. ☐ is not required as the annexes are in the English language.

(Transmittal Letter to the United States Elected Office (EO/US) [13-18]—page 6 of 9)

531 Rec'd PCT/PTC 14 JAN 2002

10. ☒ An oath or declaration of the inventor (35 U.S.C. § 371(c)(4)) complying with 35 U.S.C. § 115
- a. ☐ was previously submitted by applicant on \_\_\_\_\_. (Date)
  - b. ☐ is submitted herewith, and such oath or declaration
    - i. ☐ is attached to the application.
    - ii. ☐ identifies the application and any amendments under PCT Article 19 that were transmitted as stated in points 3(b) or 3(c) and 5(b); and states that they were reviewed by the inventor as required by 37 C.F.R. § 1.70.
  - c. ☒ will follow.

II. Other document(s) or information included:

11. ☒ An International Search Report (PCT/ISA/210) or Declaration under PCT Article 17(2)(a):
- a. ☒ is transmitted herewith.
  - b. ☐ has been transmitted by the International Bureau.  
Date of mailing (from form PCT/IB/308): \_\_\_\_\_.
  - c. ☐ is not required, as the application was searched by the United States International Searching Authority.
  - d. ☐ will be transmitted promptly upon request.
  - e. ☐ has been submitted by applicant on \_\_\_\_\_. (Date)
12. ☒ An Information Disclosure Statement under 37 C.F.R. §§ 1.97 and 1.98:
- a. ☒ is transmitted herewith.

Also transmitted herewith is/are:

- ☐ Form PTO-1449 (PTO/SB/08A and 08B).
  - ☐ Copies of citations listed.
  - b. ☐ will be transmitted within THREE MONTHS of the date of submission of requirements under 35 U.S.C. § 371(c).
  - c. ☐ was previously submitted by applicant on \_\_\_\_\_. (Date)
13. ☐ An assignment document is transmitted herewith for recording.
- A separate ☐ "COVER SHEET FOR ASSIGNMENT (DOCUMENT) ACCOMPANYING NEW PATENT APPLICATION" or ☐ FORM PTO 1595 is also attached.
- \_\_\_\_\_  
\_\_\_\_\_  
\_\_\_\_\_

10/031190

531 Rec'd PCT/PT 14 JAN 2002

14. ☒ Additional documents:
- a. ☒ Copy of request (PCT/RO/101)
  - b. ☒ International Publication No. WO: 01/22082 A1
    - i. ☐ Specification, claims and drawing
    - ii. ☐ Front page only
  - c. ☒ Preliminary amendment (37 C.F.R. § 1.121)
  - d. ☒ Other  
PCT/ISA/220; PCT/IPEA/416
- 
- 
15. ☒ The above checked items are being transmitted
- a. ☒ before 30 months from any claimed priority date.
  - b. ☐ after 30 months.
16. ☐ Certain requirements under 35 U.S.C. § 371 were previously submitted by the applicant on \_\_\_\_\_, namely:
- 
- 
- 
- 

### AUTHORIZATION TO CHARGE ADDITIONAL FEES

**WARNING:** Accurately count claims, especially multiple dependant claims, to avoid unexpected high charges if extra claims are authorized.

**NOTE:** "A written request may be submitted in an application that is an authorization to treat any concurrent or future reply, requiring a petition for an extension of time under this paragraph for its timely submission, as incorporating a petition for extension of time for the appropriate length of time. An authorization to charge all required fees, fees under § 1.17, or all required extension of time fees will be treated as a constructive petition for an extension of time in any concurrent or future reply requiring a petition for an extension of time under this paragraph for its timely submission. Submission of the fee set forth in § 1.17(a) will also be treated as a constructive petition for an extension of time in any concurrent reply requiring a petition for an extension of time under this paragraph for its timely submission." 37 C.F.R. § 1.136(a)(3).

**NOTE:** "Amounts of twenty-five dollars or less will not be returned unless specifically requested within a reasonable time, nor will the payer be notified of such amounts; amounts over twenty-five dollars may be returned by check or, if requested, by credit to a deposit account." 37 C.F.R. § 1.26(a).

☒ Please charge, in the manner authorized above, the following additional fees that may be required by this paper and during the entire pendency of this application:

☒ 37 C.F.R. § 1.492(a)(1), (2), (3), and (4) (filing fees)

**WARNING:** Because failure to pay the national fee within 30 months without extension (37 C.F.R. § 1.495(b)(2)) results in abandonment of the application, it would be best to always check the above box.

(Transmittal Letter to the United States Elected Office (EO/US) [13-18]—page 8 of 9)



10034190 10/03/190/  
531 Rec'd PCT/PT 14 JAN 2002

- ☐ 37 C.F.R. § 1.492(b), (c) and (d) (presentation of extra claims)

NOTE: Because additional fees for excess or multiple dependent claims not paid on filing or on later presentation must only be paid or these claims cancelled by amendment prior to the expiration of the time period set for response by the PTO in any notice of fee deficiency (37 C.F.R. § 1.492(d)), it might be best not to authorize the PTO to charge additional claim fees, except possible when dealing with amendments after final action.

- ☒ 37 C.F.R. § 1.17 (application processing fees)  
☒ 37 C.F.R. § 1.17(a)(1)–(5) (extension fees pursuant to § 1.136(a).  
☐ 37 C.F.R. § 1.18 (issue fee at or before mailing of Notice of Allowance, pursuant to 37 C.F.R. § 1.311(b))

NOTE: Where an authorization to charge the issue fee to a deposit account has been filed before the mailing of a Notice of Allowance, the issue fee will be automatically charged to the deposit account at the time of mailing the notice of allowance. 37 C.F.R. § 1.311(b).

NOTE: 37 C.F.R. § 1.28(b) requires "Notification of any change in loss of entitlement to small entity status must be filed in the application . . . prior to paying, or at the time of paying . . . issue fee." From the wording of 37 C.F.R. § 1.28(b): (a) notification of change of status must be made even if the fee is paid as "other than a small entity" and (b) no notification is required if the change is to another small entity.

- ☐ 37 C.F.R. § 1.492(e) and (f) (surcharge fees for filing the declaration and/or filing an English translation of an International Application later than 30 months after the priority date).

  
SIGNATURE OF PRACTITIONERScott A. McCollister

(type or print name of practitioner)

Reg. No.: 33,961

Tel. No.: (216 ) 861-5582

Fay, Sharpe, Fagan, Minnich & McKee, LLP

Customer No.:

P.O. Address

1100 Superior Avenue, Seventh Floor  
Cleveland, OH 44114-2518

10034498-898402  
107031190  
531 Rec'd PCT/PTC 14 JAN 2002

PATENT

**IN THE UNITED STATES PATENT AND TRADEMARK OFFICE**

IN RE APPLICATION OF : YEAMAN, Steve et al.  
FOR : **METHOD TO STUDY INSULIN  
ACTION**  
SERIAL NO. : Unknown  
FILED : Herewith  
ATTORNEY DOCKET NO. : YOU 2 0081

Cleveland, Ohio 44114-2518  
January 14, 2002

**PRELIMINARY AMENDMENT**

Assistant Commissioner For Patents  
Washington, D.C. 20231

Dear Sir:

Prior to calculation of the filing fee and substantive examination of the above-referenced patent application, Applicants respectfully request amendment of the application as follows. A clean copy of the claims appears below and a marked-up version is attached as an appendix.

**IN THE CLAIMS:**

3. A method of studying insulin action in a cell line according to claim 1, wherein the cell line is or is derived from an insulin associated tissue.

4. A method of studying insulin action in a cell line according to claim 1, wherein the cell line is or is derived from an insulin target tissue.

5. A method of studying insulin action in a cell line according to claim 1, wherein the cell line is or is derived from a tissue selected from muscle, fat or liver.

6. A method of studying insulin action in a cell line according to claim 1, wherein the cell line is a transformed cell line.

7. A method of determining whether an agent can modulate insulin activity in muscle, said method comprising contacting a cell line as defined in claim 1 with an agent, and determining whether the agent modulates insulin activity.

8. A method according to claim 7 wherein the cell line is contacted with the agent whilst in the non-immortalised state.

9. A cell line as defined in claim 1 wherein the cell line is for subsequent use for studying Type-2-diabetes.

Please add the following new claims:

10. A method of studying insulin action in a cell line according to claim 2, wherein the cell line is or is derived from an insulin associated tissue.

11. A method of studying insulin action in a cell line according to claim 2, wherein the cell line is or is derived from an insulin target tissue.

12. A method of studying insulin action in a cell line according to claim 3, wherein the cell line is or is derived from an insulin target tissue.

13. A method of studying insulin action in a cell line according to claim 2, wherein the cell line is or is derived from a tissue selected from muscle, fat or liver.

14. A method of studying insulin action in a cell line according to claim 3, wherein the cell line is or is derived from a tissue selected from muscle, fat or liver.

15. A method of studying insulin action in a cell line according to claim 4, wherein the cell line is or is derived from a tissue selected from muscle, fat or liver.

16. A method of studying insulin action in a cell line according to claim 2, wherein the cell line is a transformed cell line.

17. A method of studying insulin action in a cell line according to claim 3, wherein the cell line is a transformed cell line.

18. A method of studying insulin action in a cell line according to claim 4, wherein the cell line is a transformed cell line.


19. A method of studying insulin action in a cell line according to claim 5, wherein the cell line is a transformed cell line.

**Remarks**

Applicants respectfully request that the foregoing amendments be entered prior to substantive examination of the application.

Respectfully submitted,  
FAY, SHARPE, FAGAN  
MINNICH & MCKEE, LLP

Date: January 14, 2001

  
Scott A. McCollister  
Reg. No. 33,961  
1100 Superior Avenue, 7th Floor  
Cleveland, Ohio 44114-2518  
(216) 861-5582

**CERTIFICATE OF MAILING**

I hereby certify that this **PRELIMINARY AMENDMENT** is being deposited with the United States Postal Service as **EXPRESS MAIL** in an envelope numbered **EL805293170 US**, addressed to Assistant Commissioner for Patents, Washington, DC 20231 on January 14, 2002.

By:   
George B. George

VERSION WITH MARKINGS TO SHOW CHANGES MADE

3. A method of studying insulin action in a cell line according to [any preceding] claim 1, wherein the cell line is or is derived from an insulin associated tissue.
4. A method of studying insulin action in a cell line according to [any preceding] claim 1, wherein the cell line is or is derived from an insulin target tissue.
5. A method of studying insulin action in a cell line according to [any preceding] claim 1, wherein the cell line is or is derived from a tissue selected from muscle, fat or liver.
6. A method of studying insulin action in a cell line according to [any preceding] claim 1, wherein the cell line is a transformed cell line.
7. A method of determining whether an agent can modulate insulin activity in muscle, said method comprising contacting a cell line as defined in [any preceding] claim 1 with an agent, and determining whether the agent modulates insulin activity.
8. A method according to [any of claims 2 to] claim 7 wherein the cell line is contacted with the agent whilst in the non-immortalised state.
9. A cell line as defined in [any preceding] claim 1 wherein the cell line is for subsequent use for studying Type-2-diabetes.

Please add the following new claims:

10. A method of studying insulin action in a cell line according to claim 2, wherein the cell line is or is derived from an insulin associated tissue.
11. A method of studying insulin action in a cell line according to claim 2, wherein the cell line is or is derived from an insulin target tissue.
12. A method of studying insulin action in a cell line according to claim 3,

wherein the cell line is or is derived from an insulin target tissue.

13. A method of studying insulin action in a cell line according to claim 2, wherein the cell line is or is derived from a tissue selected from muscle, fat or liver.

14. A method of studying insulin action in a cell line according to claim 3, wherein the cell line is or is derived from a tissue selected from muscle, fat or liver.

15. A method of studying insulin action in a cell line according to claim 4, wherein the cell line is or is derived from a tissue selected from muscle, fat or liver.

16. A method of studying insulin action in a cell line according to claim 2, wherein the cell line is a transformed cell line.

17. A method of studying insulin action in a cell line according to claim 3, wherein the cell line is a transformed cell line.

18. A method of studying insulin action in a cell line according to claim 4, wherein the cell line is a transformed cell line.

19. A method of studying insulin action in a cell line according to claim 5, wherein the cell line is a transformed cell line.

**C:\DATA\2002\JA02\YOU20081.PAM.doc**

## METHOD TO STUDY INSULIN ACTION

### Field of the Invention

- 5 The invention relates to a method for the study of the action of insulin. In particular, the invention relates to a method for studying type-2 diabetes.

### Background to the Invention

- 10 Diabetes is a major health issue, affecting over 1 million people in the United Kingdom alone. It has been estimated that diabetes and its sequelae account for as much as 5-6% of total NHS spending.

- The development of type-2 diabetes is caused by a failure of the pancreas to secrete  
15 insulin in sufficient quantities. Type-2 diabetes is usually preceded by a period of insulin resistance. Insulin resistance is caused by impairment of the ability of insulin to properly regulate glucose metabolism. Since muscle is the major site of insulin stimulated glucose disposal, therapeutic treatments compensating for insulin resistance in muscle may delay or prevent the onset of diabetes. Therefore, there is a need to  
20 fully understand the mechanism of insulin action in muscle.

- Considerable effort has been directed towards studying the molecular basis of insulin resistance in human muscle. One approach has been to use *ex vivo* preparations of human muscle (Shepherd *et al.*, 1997: Diabetologia vol 40 pp1172-1177; Shepherd  
25 *et al.*, 1997: J. Biol. Chem. vol 272 pp19000-19007). However, studies in intact muscle are technically very demanding due to the possibility of inadvertent stimulation of glucose metabolism by pathways related to muscle contraction. Furthermore, the size of the muscle sample available is often limited. *Ex vivo* muscle preparations are unsuited to experiments which require long term treatments (e.g. testing of drugs) or

manipulations (e.g. transfection studies). Clearly, there are problems associated with prior art *ex vivo* techniques for the study of insulin action.

An alternative prior art approach to the study of insulin action in muscle cells involves the preparation of primary cultures of human myoblasts (Hurel *et al.*, 1996: Biochemical Journal vol 320 pp871-877). Using this approach it has been possible to isolate myoblasts which retain the capability to differentiate into myotubes. However, there are several problems associated with primary cultures of muscle explants. Firstly, the number of cell divisions which the cells will undergo in such cultures is limited and the cells soon senesce, making it impossible to obtain clonal cell lines. Secondly, contamination by fibroblasts is a major problem and affects the interpretation of data obtained from such prior art cultures. Furthermore, growth of these cells is slow (doubling time 4-7 days) and the rate of growth of cells is inversely proportional to the age of the subject from which they were obtained. This slow growth causes practical difficulties associated with the longer periods of cell culture required. In addition, the slow growth can lead to domination of the cell pool by faster growing clones, thus affecting the characteristics of the culture over time. It has been observed that after 10-15 passages these prior art primary muscle cultures lose muscle phenotype. This is a problem.

The present invention seeks to overcome the problems associated with the prior art.

Aspects of the present invention are set out in the claims and are described below.

## Summary of the Invention

In a first aspect, the invention relates to a method of studying insulin action in a cell line, wherein the cell line is an immortalised cell line, said method comprising: contacting the cell line with a factor, and determining whether the factor affects insulin action.



The term "immortalised" refers to a cell line which is capable of being cultured through numerous generations without significant senescence or loss of viability.

5 Preferably, "immortalised" cell lines according to the invention are capable of being cultured indefinitely without encountering a 'crisis' stage.

The "factor" can be any suitable entity for investigation. Without wishing to be bound by theory, it may be a chemical compound or composition, a nucleotide sequence, the expression product of a nucleotide sequence, or a physical factor such as a temperature  
10 change and/or an electrical stimulus. The "factor" may be a physiological event, such as exercise or the mimicking of exercise, or it may refer to cellular contraction or signalling events known to be or suspected of being involved in muscle contraction.

The term "insulin action" includes the action of insulin itself or an entity capable of  
15 affecting the action of insulin. In a preferred embodiment, the insulin action is associated with Type-2 diabetes.

The term "affects insulin action" is used herein to mean that insulin action is enhanced, increased, augmented, inhibited, reversed, down-regulated or in some way modulated.  
20

The term "affects" is also intended to include mimicking of the effect(s) of insulin, altering the endogenous effect(s) of insulin, or modulating one or more of the effect(s) of insulin. These effect(s) of insulin may be those found in cells or tissues derived from an organism affected by diabetes, such as type-2 diabetes, or may be found in  
25 cells or tissues derived from an organism which is not affected by diabetes such as type-2 diabetes.

In another aspect, the invention relates to a method of studying insulin action in a cell line, wherein the cell line is a conditionally immortalised cell line, said method  
30 comprising: converting the cell line from an immortalised state to a non-immortalised

state; contacting the cell line when in the non-immortalised state with a factor, and determining whether the factor affects or mimics insulin action.

The term "conditionally immortalised" means a cell that is capable of being in two states: a first state wherein the cell is in an immortalised form; and a second state wherein the cell is in a non-immortalised form, preferably being the same as or similar to the wild type cell. The cells are capable of being converted from one state to the other by changing the environmental conditions of the cell line. By way of example, any one or more of the following parameters may cause said conversion: temperature, pH, pressure, the presence or absence of specific chemical(s). Typically the cells are prepared by transforming a wild type cell with a reagent which converts the wild type cell to the conditionally immortalised cell.

In one embodiment, the conversion can be achieved, by way of example, with the temperature sensitive tsA58 variant of the large T-antigen. In order to convert the immortalised cell line to the non-immortalised state using the tsA58 large T-antigen as the immortalising agent, the cell line could for example be incubated at elevated temperature, such as 39°C.

In a preferred aspect, the reagent is under the control of an inducible element.

A preferred example of an inducible element is the tamoxifen-responsive estrogen receptor. Preferably this inducible estrogen receptor is fused to an effector domain, for example E1a. Preferably the inducible estrogen receptor is present as an E1a-estrogen receptor chimera. This is discussed in more detail below.

In a preferred aspect, the conditionally immortalised cell is prepared by transfecting (transducing) a wild type cell with a viral vector, preferably a retroviral vector. This topic is discussed at length in (Coffin *et al.*, (ed.s) 1997 "Retroviruses" Cold Spring Harbour Laboratory Press (USA) which is incorporated herein by reference).

In another aspect, the invention relates to a method of studying insulin action in a cell line, wherein the cell line is or is derived from an insulin associated tissue.

An insulin associated tissue is any tissue which is either known or suspected of being involved in some way with insulin. This involvement may be direct, such as tissues which produce insulin, or which control or affect the production of insulin. An insulin associated tissue may be one which responds to insulin in some way, for example by altering its metabolism in response to the presence or absence of insulin, or one which has developed resistance to the action of insulin, or resistance to the presence or absence of insulin.

In another aspect, the invention relates to a method of studying insulin action in a cell line, wherein the cell line is or is derived from an insulin target tissue.

An "insulin target tissue" is a tissue in which insulin has an effect. This term includes tissues in which insulin would normally have an effect, but which may have developed resistance to the action of insulin. This term also includes tissues in which insulin would not normally have an effect, but may have developed a sensitivity to the action of insulin.

In another aspect, the invention relates to a method of studying insulin action in a cell line, wherein the cell line is or is derived from a tissue selected from muscle, fat or liver. In a preferred embodiment, the invention relates to a method of studying insulin action in a cell line which is, or is derived from, muscle.

In another aspect, the invention relates to a method of studying insulin action in a cell line, wherein the cell line is a transformed cell line.

Transformation may be caused by a number of factors. For example, transformation may be brought about via the expression of a transforming oncogene in the cell(s) of interest. Transformation may be assessed by one or more criteria which are indicative

of the transformed phenotype, for example, a rounded morphology, loss of contact inhibition, growth in soft agar, focus formation, or any other suitable property or marker of transformation known to those skilled in the art.

5 In another aspect, the invention relates to a method of determining whether an agent can modulate insulin activity in muscle, said method comprising contacting a cell line with an agent, and determining whether the agent modulates insulin activity.

10 In another aspect, the invention relates to a method of studying insulin action in a conditionally immortalised cell line wherein the cell line is contacted with the agent whilst in the non-immortalised state.

In another aspect, the invention relates to a cell line as described herein, wherein the cell line is for subsequent use for studying Type-2 diabetes.

In another aspect, the invention relates to a vector for use in gene therapy wherein the vector is or comprises a cell line as described herein.

Determining whether a factor affects or mimics insulin refers to the assessment of one or more of the effects of insulin in the presence and absence of the factor(s), and deciding whether the factor(s) have influenced one or more of these characteristic(s) or effect(s). Examples of effects of insulin which might be monitored in order to determine whether or not a factor affects or mimics insulin may include measuring the expression levels of one or more molecules believed to be involved in insulin signalling or glucose metabolism. Other effects which might be monitored include, but are not limited to, measuring the stimulation of one or more of the glucose metabolism and/or insulin-related signalling pathways, monitoring the levels of glycogen synthesis or breakdown, or assessing the activity of enzymes such as glycogen synthase. If any of these characteristics or effects is found to be different in the presence or absence of one or more factor(s), then said factor(s) would be

considered to have affected or mimicked insulin action. This aspect is discussed in more detail below.

There exist immortalised muscle cell lines which are currently used for studies of insulin action. However, these prior art cell lines were derived from rodents (e.g. L6 and C2C12). Whilst these cell lines may exhibit myogenic phenotype, the insulin responses in them are poor and do not truly reflect the responses seen in intact human muscle. Such prior art rodent cell lines are therefore of limited value in studying the action of insulin in human muscle. The present invention is therefore advantageous since it provides a means for the study of insulin action in human muscle cells.

#### Detailed Description of the Invention

Cell lines for use in the present invention may be generated in a variety of ways. For example, it is disclosed herein that human myoblast cultures may be conditionally immortalised using at least two different approaches; firstly, using the temperature sensitive form of the large T-antigen and secondly, using the E1a-estrogen receptor chimera. These techniques are described in more detail below.

When expressed in cells, the temperature sensitive tsA58 mutant of the SV40 large T-antigen may result in immortalisation, so long as the cells are grown at a permissive temperature (such as 33°C). Once the temperature is raised to greater than 37°C (for example 39°C) then the tsA58 is functionally inactivated and the cell growth characteristics revert to being similar to those of the parental cells. The tsA58 large T-antigen may be introduced into primary cells by any suitable means. Advantageously, it may be introduced using amphotropic retroviruses which provide high transfection efficiency combined with stable integration into chromosomal DNA (Stamps *et al.*, 1994 Int. J. Cancer vol 57 pp 865-874). After the tsA58 is introduced into the cells, the immortalised cells may be maintained at 33°C in appropriate media.

In another embodiment, cells may be advantageously immortalised using a conditionally active form of the E1a immortalising oncogene. This oncogene is a chimera comprising E1a fused with a Gly525Arg mutant of the C-terminus (amino acids 281-599) of the estrogen receptor. This mutant will not bind estradiol but will bind 4-hydroxy tamoxifen. The E1a chimera is active in the presence of 4-hydroxy tamoxifen, but removal of this drug from the growth medium allows binding of hsp-90 to the chimera which results in the inactivation of the E1a, thus allowing the cell to return to a non transformed phenotype.

10 Thus, the invention relates to cell(s) generated using the methods described herein. Furthermore, the invention relates to cell(s) having substantially the same properties as cell(s) described herein. Examples of particular cell(s) and the methods for their production are disclosed herein, such as in Example 1 and elsewhere. It will be understood that said examples are illustrative to the invention, and not in any way  
15 limiting.

There are numerous advantages to using the conditional immortalisation approach which include, among others; (i) all immortalised cells are conferred with the same growth advantage so the characteristics of the cultures remain stable (ii) expansion of cell cultures is much more rapid thus expediting experimental processes such as clonal selection (iii) the immortalization/transformation is reversible, allowing return to a normal muscle phenotype and (iv) cells do not have to undergo chromosomal rearrangement to gain growth advantage and they are far more likely to retain a normal karyotype than immortal cell lines which may arise spontaneously after a crisis period.

25           Immortalised human muscle cells as described below may be used in conjunction with existing cell culture models in a method according to the invention for study of the action of insulin, for example for study of the insulin signalling pathways regulating glucose metabolism. Preferably, said methods may be applied to muscle cell lines  
30       derived from normal and/or diabetic subjects and/or subjects which have or are thought to have a heritable predisposition or susceptibility to the development of diabetes.

It is envisaged that methods according to the invention may identify one or more parts of the insulin signalling cascade which are deranged in human muscle in the diabetic state. Clearly, the methods of the invention may be applied to the study of such defects, and may be usefully employed in carrying out high throughput screening directed at identifying candidate molecule(s) or factors which in some way alleviate, inhibit, reverse or modulate such defect(s).

It would be advantageous to use a transfection approach in the cell lines or methods of the current invention in order to investigate the effect of various factors or wild-type signalling molecules on insulin signalling. Such molecules or factors may be identified by the methods of the current invention, or may be otherwise identified.

It is envisaged that the methods of the current invention may be applied to the analysis of differences in gene expression between normal and diabetic tissues using gene array and/or proteomic methodologies.

We also anticipate that the cell lines and/or methods of the present invention will be of use in studying other diseases affecting skeletal muscle, for example muscular dystrophy or other muscle disorders.

The present invention will now be described, for the purpose of illustration only, by way of the following examples.

## EXAMPLE 1: CREATION AND STUDY OF IMMORTALISED RODENT MUSCLE CELL LINES

Primary cultures of mouse muscle precursor cells are derived from "Immortomice" by mincing the tissue and allowing the viable cells to settle onto collagen coated plates in HamsF12 media.

Immortomice are a transgenic line of mice in which a transgene has been introduced encoding the tsA58 temperature sensitive mutant of the large T-antigen under the control of the H2kb promoter. This means that the tsA58 is not actually expressed in most tissues of the mice but is induced to express in cell lines derived from these mice  
5 when  $\gamma$ -interferon is added to the cell medium to activate the H2kb promoter.

Therefore, these cell lines are immortalised on the condition they are grown at the permissive temperature of 33°C in the presence of  $\gamma$ -interferon. To induce differentiation into fused myotubes the cells are allowed to grow to confluency, then  $\gamma$ -  
10 interferon is withdrawn to stop production of the immortalising antigen, and any remaining large T-antigen is inactivated by raising the temperature to 39°C, thus preventing further growth. On withdrawal of serum, the cells fuse into myotubes. Three myogenic cell lines are derived in this way (C10, SF1 and SF2).

15 At this stage the characteristics of the insulin mediated pathways are compared with other systems used for the study of muscle i.e. intact human skeletal muscle, primary cultures of human muscle and with widely used rodent muscle cell lines which were derived from conventional spontaneous immortalization strategies (e.g. L6 cells).

20 It is demonstrated that the C10 mouse muscle cells and intact human muscle both express the full range of adapter subunit isoforms of the crucial signal transduction enzyme PI 3-kinase. These isoforms are not expressed in the long term primary (non-immortalised) cell cultures of human muscle nor in the L6 cell line.

25 The regulation of the PI3-Kinase splice variants by insulin in C10 cells is very similar to that seen in intact human skeletal muscle in that both p85 and p50 show very high levels of recruitment to signalling complexes whereas p55 shows very low levels of recruitment. Similarly, C10 cells express high levels of glycogen synthase, a crucial enzyme in glucose metabolism, whereas levels are much lower in human muscle  
30 primary (non-immortalised) cell cultures and the L6 cell line.



Overall, these results demonstrate that the conditional immortalisation of the mouse cells allows many of the important characteristics of intact muscle to be retained whereas these are lost in long term primary cultures of human muscle and are also not found in currently available rodent muscle cell lines such as the L6 cell line.

5

## EXAMPLE 2: CREATION OF IMMORTALISED HUMAN MUSCLE CELL LINES

In order to establish primary human muscle cultures, muscle biopsies from type-2  
10 diabetics, non diabetic first degree relatives of type-2 diabetics and control subjects are obtained, and muscle cells are cultured using methods essentially as described in (Hurel *et al.*, 1996: Biochemical Journal vol 320 pp871-877). Biopsies from first degree relatives of type-2 diabetics are included as it has been shown that these subjects share with their diabetic relatives a predisposition to the development of  
15 insulin resistance which strongly suggests a genetic basis for insulin resistance. Similarly, the type-2 diabetics chosen for this study have a first degree relative with type-2 diabetes or insulin resistance in order to increase the likelihood that their diabetes originates from a genetic cause. Six subjects in each group are recruited, all subjects being matched for age, sex and body mass index.

20

Briefly, this is carried out as taught in (Hurel *et al.*, 1996: Biochemical Journal vol 320 pp871-877), and as described in Example 3.

### Primary Cell Culture

25 Muscle biopsy samples (approx. 0.10-0.25 g) are obtained from the gastrocnemius muscle of subjects. Tissue is rinsed in culture medium (Ham's nutrient culture mixture F10 with 20% foetal calf serum, 1% chick embryo extract, 10000 units/ml penicillin and 2  $\mu$ g/ml streptomycin). All visible connective tissue and fat is removed using forceps, and the biopsy samples are chopped finely with scissors and transferred to a  
30 small sterile flask containing 0.05 unit/ml trypsin and 0.05 mM EDTA in PBS. After stirring gently at 37°C for 15 min, the particulate debris is allowed to settle and the

supernatant is removed and centrifuged at 550 g for 5 min. Pellets are collected and resuspended in conditioning medium. The cells are then grown to confluency in culture medium in 25cm<sup>2</sup> culture flasks coated with 1% gelatin, and are then transferred to 75cm<sup>2</sup> flasks and ultimately to 6cm<sup>2</sup> wells. Fusion into myotubes and immunocytochemical staining with anti-desmin and anti-(fibroblast surface protein) antibodies confirms the predominant presence of myoblasts.

### Characterisation of Muscle Cell Cultures

Myoblast lines are initially tested for their ability to differentiate into myotubes.

The ability of the cells to fuse into multinucleated myotubes is monitored over several days and is assessed morphologically and/or by staining for the muscle marker desmin and/or assaying creatine kinase activity.

15

These primary cultures of human myoblasts retain insulin resistant characteristics for several passages/generations. Said characteristics are maintained at the time of transfection with immortalising agents.

These primary cell lines are then immortalised. The cultures are transfected with an amphotropic, replication defective retrovirus containing a neomycin selection marker and either the tsA58-Large T-antigen or the E1a-estrogen receptor chimera.

Untransfected cells are eliminated using G-418 selection.

25

Contaminating fibroblasts are removed from pooled cells by FACS sorting using antibodies to fibroblast surface protein, and clonal lines are then derived.

The cell lines produced maintain insulin resistant characteristics in culture with the added advantage of not having been subject to the diabetic milieu which can itself contribute to the insulin resistance seen at the cellular level.

30

### EXAMPLE 3: STUDY OF INSULIN ACTION IN IMMORTALISED HUMAN MUSCLE CELL LINES

- 5 Human cell lines produced as in Example 2 are used to study the action of insulin.

#### Comparison of insulin responses of cell lines

- Expression levels of molecules involved in insulin signalling and glucose metabolism are studied, and the action of insulin on both metabolic and signalling pathways is  
10 studied.

- Western blotting is used to determine levels of expression of key molecules involved in insulin signalling and glucose metabolism. This is carried out using commonly available antibodies to molecules such as the Glut-1 and Glut-4 glucose transporters,  
15 p70S6-kinase, glycogen synthase, glycogen synthase kinase-3, insulin receptor, IRS-1, IRS-2, protein kinase-B and various isoforms of PI3-kinase.

- Insulin stimulation of glucose metabolism and/or signalling pathways in different cell lines is studied. Conditionally immortalised myoblasts, myotubes (both normal and  
20 diabetic) and L6 myotubes are serum starved for 3 hours, then stimulated for 20 minutes with low (1 nM), medium (10 nM) or high (100 nM) doses of insulin and glucose uptake is assessed using the standard <sup>3</sup>H-2-deoxyglucose uptake method (Shepherd *et al.*, 1995: Biochemical Journal vol 305 pp25-28).

- 25 The ability of insulin to stimulate glycogen synthesis is determined by measuring the incorporation of U-<sup>14</sup>C-glucose into glycogen, and insulin stimulated glycogen synthase activity is determined using activity ratios as described in (Shepherd *et al.*, 1995: Biochemical Journal vol 305 pp25-28).

- 30 Formation of insulin stimulated phosphotyrosine signalling complexes is assessed. Cells are stimulated with insulin, and tyrosine phosphorylated polypeptides are

immunoprecipitated using antiphosphotyrosine antibodies. Immunoprecipitates are western blotted with antiphosphotyrosine antibodies, and/or with antibodies to the insulin receptor, IRS-1, IRS-2 or the p85 subunit of PI 3-kinase.

- 5 To compare the activation of key downstream protein kinase cascades, stimulated cells are lysed and PKB, p70-S6 kinase and MAP Kinase are immunoprecipitated from stimulated and unstimulated control cells using specific antibodies. Kinase activity in immunoprecipitates is determined using myelin basic protein based peptide substrate (APRTPGGRR) for MAP Kinase assays, the crosstide peptide (GRPRTSSFAEG) for  
10 PKB assays and the S6 peptide substrate (RRRLSSLRA) for p70 S6 kinase assays. PI3-kinase activity is assayed in immunoprecipitates as described in (Navé *et al.*, 1996: Biochemical Journal vol 318 pp55-60).

#### **Treatment with Insulin**

- 15 At 16 h prior to the studies, cells are transferred into serum-free medium. When required, insulin is added at a concentration of 1  $\mu$ M. For inhibition studies, cells are preincubated with 100 nM wortmannin or 100 nM rapamycin for 15 min, or with 50  $\mu$ M PD98059 for 1 h, prior to the addition of insulin.

#### **20 Preparation of Cell Extracts**

Following incubation of cells under appropriate conditions (ie. with or without insulin stimulation etc.), the cell monolayers are washed rapidly five times with ice-cold PBS.

- Extraction buffer [100 mM Tris/HCl, 100 mM KCl, 2mM EDTA, 25 mM KF, 0.1%  
25 (v/v) Triton X-100, 1 mM benzamidine, 0.1 mM Na<sub>3</sub>VO<sub>4</sub>, 1 mg/ml glycogen, pH 7.3, containing 10  $\mu$ g/ml pepstatin, 10  $\mu$ g/ml antipain and 10  $\mu$ g/ml leupeptin] is added (200  $\mu$ l per 6 cm<sup>2</sup> plate), and cells are scraped and immediately frozen in liquid N<sub>2</sub>.

- Prior to analysis, samples are thawed, dispersed by sonication for 60s (Sonibath;  
30 Dawe) and then centrifuged at 13000 g for 5 min at 4°C. The supernatants are retained and the protein concentration is determined.

### Fractionation of Cell Extracts on Mono Q

Following centrifugation at 13000 g, the supernatant is passed through a 0.2  $\mu$ m-pore-size filter and the extract, containing approx. 1 mg of protein, is diluted in 5 ml of  
5 buffer A (50 mM sodium glycerophosphate, 1 mM EGTA, 1 mM benzamidine, 1 mM dithiothreitol, 0.1 mM  $\text{Na}_3\text{VO}_4$ , pH 7.4, containing 1  $\mu$ g/ml each of pepstatin, antipain and leupeptin) and loaded on to an FPLC Mono Q column (Pharmacia) equilibrated in the same buffer. After washing extensively with buffer A, proteins are eluted with a linear salt gradient from 0 to 0.5 M NaCl in 20 ml of buffer A. Fractions of 0.5 ml are  
10 collected, and 10  $\mu$ l of each fraction is assayed for PKB activity as described below or is subjected to immunoblotting using anti-PKB antibodies.

### Immunoprecipitation and Assay of Kinases

Samples (30  $\mu$ l) of cell extract supernatants containing approx. 5  $\mu$ g of protein are  
15 incubated with antibodies to p70<sup>s6K</sup> (0.2  $\mu$ g), p90<sup>s6K</sup> (0.5  $\mu$ g) or ERK2 (0.4  $\mu$ g) in a total volume of 40  $\mu$ l for 2 h at 0°C. Protein A (2 mg) immobilized on Sepharose 4B-C1 prepared at 100 mg/ml in extraction buffer is added, and the incubation is continued at 4°C for 1 h with occasional shaking.

20 The immobilized immune complexes are recovered by centrifugation at 13000 g, and washed twice with extraction buffer and then once with buffer A. The pellet is resuspended to 20  $\mu$ l in buffer A, and the kinases are assayed in a total volume of 40  $\mu$ l containing 50 mM sodium glycerophosphate, pH 7.4, 50  $\mu$ M [ $\gamma$ -<sup>32</sup>P]ATP (approx. 4000 c.p.m./pmol), 10 mM  $\text{MgCl}_2$ , 0.5 mM benzamidine, 0.5 mM dithiothreitol,  
25 0.5mM EGTA, 0.05 mM  $\text{Na}_3\text{VO}_4$ , 2.5  $\mu$ M PKI, and including either 50  $\mu$ M s6 kinase substrate peptide for the assay of p70<sup>s6K</sup> and p90<sup>s6K</sup>, or 0.25 mg/ml myelin basic protein for the assay of ERK2. After a 30 min incubation at 30°C, the radiolabelled peptide product is recovered by centrifugation, and 25  $\mu$ l of the supernatant is spotted on to Whatman P81 phosphocellulose paper squares. After washing in 175 mM  
30 phosphoric acid with four changes, the papers are dried and phosphate incorporation is determined by liquid scintillation counting.

GSK-3 immunoprecipitations are carried out using a mixture of anti-GSK-3 $\alpha$  and anti-GSK-3 $\beta$  antibodies pre-absorbed in Pansorbin. Cell extracts are prepared in extraction buffer as described above but with the addition of 100 nM okadaic acid. Aliquots  
5 containing approx. 10  $\mu$ g of protein are diluted to 150  $\mu$ l by addition of buffer A. Following conjugation with antibody/Pansorbin for 2 h at 4°C, samples are centrifuged at 13000 g to recover the immune complex and the supernatant is removed. The pellet is washed once with extraction buffer and twice with buffer A. The pellet is then resuspended to 10  $\mu$ l in buffer A and GSK-3 is assayed in a total volume of 20  $\mu$ l  
10 containing 25 mM sodium glycerophosphate, pH 7.4, 100 mM NaCl, 25  $\mu$ M GSK-3 phosphopeptide, 50  $\mu$ M [ $\gamma$ -<sup>32</sup>P]ATP, 10 mM MgCl<sub>2</sub>, 0.5 mM benzamidine, 0.5 mM dithiothreitol, 0.5 mM EGTA, 0.05 mM Na<sub>3</sub>VO<sub>4</sub> and 2.5 mM PK1. After a 30 min incubation at 30°C, the radiolabelled peptide product is recovered and quantified as above. GSK-3 is assayed using substrate peptide as described in Borthwick *et al.*,  
15 (1995) Biochem. Biophys. Res. Comm. vol 210 pp738-745.

PKB is immunoprecipitated in an identical manner to that for GSK-3, except that anti-(PKB pleckstrin homology domain) antibodies (1  $\mu$ l) are used instead of anti-GSK-3 antibodies. PKB activity is assayed against 100  $\mu$ M Crosstide under the conditions  
20 described above.

#### Assay of GS

Following the indicated treatments, cell extracts are prepared in extraction buffer and GS activity is assayed as incorporation of [<sup>14</sup>C]glucose from UDP-[U-<sup>14</sup>C]glucose into  
25 glycogen. Assays are performed in the presence of low (0.1 mM) and high (10 mM) concentrations of glucose 6-phosphate to give active and total activities of GS, and the results are expressed as fractional activity.

### Glycogen Synthesis

Glycogen synthesis is determined as [ $^{14}\text{C}$ ]glucose incorporation into glycogen. Cells are incubated for 2 h in culture medium containing [ $\text{U}^{14}\text{-C}$ ]glucose (5 mM glucose; 1.25  $\mu\text{Ci/ml}$ ) with or without insulin. The experiment is terminated by removing the medium and rapidly washing the cells five times in ice-cold PBS. Cells are lysed by the addition of 20% (w/v) KOH, which is neutralized after 1 h by the addition of 1 M HCl. The wells are aspirated and the contents boiled for 5 min. After addition of 1 mg/ml glycogen, precipitation is carried out with ethanol at 0°C for 2 h. The samples are centrifuged at 1100 g for 10 min, pellets are redissolved in water and radioactivity is determined by liquid scintillation counting.

### EXAMPLE 4: USE OF HUMAN CELL LINES IN AN ASSAY

Immortalised human muscle cell lines are produced as in Example 2.

These cell lines are used in an assay system to determine the effect(s) of candidate drugs on insulin action.

Cell lines are cultured, and contacted with the candidate drug(s), and then the insulin responses are assayed in said cells, in order to determine whether the candidate drugs have any effect on insulin action, and therefore on type-2 diabetes.

Insulin responses are assayed by monitoring expression levels of molecules involved in insulin signalling and glucose metabolism, and the action of insulin on both metabolic and signalling pathways is studied.

Western blotting is used to determine levels of expression of key molecules involved in insulin signalling and glucose metabolism. Insulin stimulation of glucose metabolism and/or signalling pathways in cell lines contacted with different candidate drug(s) are studied. Formation of insulin stimulated phosphotyrosine signalling complexes is assessed. These analyses are carried out as in Example 3.

The ability of insulin to stimulate glycogen synthesis is determined by measuring the incorporation of U-<sup>14</sup>C-glucose into glycogen, and insulin stimulated glycogen synthase activity is determined using activity ratios as described in (Shepherd *et al.*,  
5 1995: Biochemical Journal vol 305 pp25-28).

To compare the activation of key downstream protein kinase cascades, stimulated cells are lysed. The various kinases of interest are then immunoprecipitated from cells which were or were not contacted with candidate drug(s). Kinase activity in  
10 immunoprecipitates is determined as in Example 3.

Any candidate molecules shown by this assay system to affect insulin action would be considered good drug candidates for use in therapy of Type-2 diabetes.

15 All publications mentioned in the above specification are herein incorporated by reference. Various modifications and variations of the described methods and system of the invention will be apparent to those skilled in the art without departing from the scope and spirit of the invention. Although the invention has been described in connection with specific preferred embodiments, it should be understood that the  
20 invention as claimed should not be unduly limited to such specific embodiments. Indeed, various modifications of the described modes for carrying out the invention which are obvious to those skilled in this or related fields are intended to be within the scope of the following claims.



**Sequence Listing**

SEQ ID NO:1

APRTPGGRR

5 myelin basic protein based peptide substrate

SEQ ID NO:2

GRPRTSSFAEG

crosstide peptide

10

SEQ ID NO:3

RRRLSSLRA

S6 peptide substrate

CLAIMS

1. A method of studying insulin action in a cell line, wherein the cell line is an immortalised cell line, said method comprising:

5

- (a) contacting the cell line with a factor; and
- (b) determining whether the factor affects or mimics insulin action.

10 2. A method of studying insulin action in a cell line, wherein the cell line is a conditionally immortalised cell line, said method comprising;

15

- (a) converting the cell line from an immortalised state to a non-immortalised state;
- (b) contacting the cell line when in the non-immortalised state with a factor; and
- (c) determining whether the factor affects or mimics insulin action.

20

3. A method of studying insulin action in a cell line according to any preceding claim, wherein the cell line is or is derived from an insulin associated tissue.

4. A method of studying insulin action in a cell line according to any preceding  
25 claim, wherein the cell line is or is derived from an insulin target tissue.

5. A method of studying insulin action in a cell line according to any preceding claim, wherein the cell line is or is derived from a tissue selected from muscle, fat, or liver.

30

6. A method of studying insulin action in a cell line according to any preceding claim, wherein the cell line is a transformed cell line.
7. A method of determining whether an agent can modulate insulin activity in  
5 muscle, said method comprising contacting a cell line as defined in any preceding claim with an agent, and determining whether the agent modulates insulin activity.
8. A method according to any of claims 2 to 7 wherein the cell line is contacted with the agent whilst in the non-immortalised state.
- 10 9. A cell line as defined in any preceding claim wherein the cell line is for subsequent use for studying Type-2 diabetes.

(12) INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(19) World Intellectual Property Organization  
International Bureau(43) International Publication Date  
29 March 2001 (29.03.2001)

PCT

(10) International Publication Number  
**WO 01/22082 A1**

- (51) International Patent Classification<sup>7</sup>: **G01N 33/50**,  
33/74, C07K 14/72, C12N 5/00
- (21) International Application Number: PCT/GB00/02674
- (22) International Filing Date: 11 July 2000 (11.07.2000)
- (25) Filing Language: English
- (26) Publication Language: English
- (30) Priority Data:  
9916400.6 13 July 1999 (13.07.1999) GB
- (71) Applicants (*for all designated States except US*): **UNIVERSITY COLLEGE LONDON** [GB/GB]; Brook House, 2-16 Torrington Place, London WC1E 7HN (GB). **UNIVERSITY OF NEWCASTLE** [GB/GB]; Newcastle-Upon-Tyne NE1 7RU (GB).
- (72) Inventors; and
- (75) Inventors/Applicants (*for US only*): **YEAMAN, Steve** [GB/GB]; School of Biochemistry and Genetics, University of Newcastle, Framlington Place, Newcastle-Upon-Tyne NE2 4HH (GB). **SHEPHERD, Peter** [NZ/GB]; University College London, Department of Biochemistry, Gower Street, London WC1E 6BT (GB). **ZORZANO, Antonio** [ES/ES]; Universitat de Barcelona, Facultat de Biologia, Dept. de Bioquímica i Fisiològica, Avienda Diagonal, 645, E-08028 Barcelona (ES).
- (74) Agents: **HARDING, Charles, Thomas et al.**; D. Young & Co., 21 New Fetter Lane, London EC4A 1DA (GB).
- (81) Designated States (*national*): AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CR, CU, CZ, DE, DK, DM, DZ, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZW.
- (84) Designated States (*regional*): ARIPO patent (GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZW), Eurasian patent (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM), European patent (AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE), OAPI patent (BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG).
- Published:**  
— *With international search report.*
- For two-letter codes and other abbreviations, refer to the "Guidance Notes on Codes and Abbreviations" appearing at the beginning of each regular issue of the PCT Gazette.*

(54) Title: METHOD TO STUDY INSULIN ACTION

(57) Abstract: This invention relates to a method of studying insulin action in a cell line, wherein the cell line is an immortalised cell line. This method comprises contacting the cell line with a factor, and determining whether the factor affects or mimics insulin action.

WO 01/22082 A1

1003110/10.51190

WO 01/22082

PCT/GB00/02674

- 1 - 531 Rec'd PCT/PTC 14 JAN 2002

### Sequence Listing

SEQ ID NO:1

APRTPGGRR

5 myelin basic protein based peptide substrate

SEQ ID NO:2

GRPRTSSFAEG


crosside peptide

10

SEQ ID NO:3

RRRLSSLRA

S6 peptide substrate



Attorney Docket No. YOU 2 0081

**DECLARATION AND POWER OF ATTORNEY FOR PATENT APPLICATION**

As a below inventor, I hereby declare that:

My residence, post office address and citizenship are as stated below next to my name.

I believe I am the original, first and sole inventor (if only one name is listed below) or an original, first and joint inventor (if plural names are listed below) of the subject matter which is claimed and for which a patent is sought on the invention entitled:

**METHOD TO STUDY INSULIN ACTION**

the specification of which

☐ is attached hereto

☒ was filed on January 14, 2002  
Application Serial No. 10/031,190  
and was amended on  
(if applicable)

☐ was filed \_\_\_\_\_.

I hereby state that I have reviewed and understand the contents of the above identified specification, including the claims, as amended by any amendment referred to above.

I acknowledge the duty to disclose information which is material to the examination of this application in accordance with Title 37, Code of Federal Regulations, 1.56 (a).

I hereby claim foreign priority benefits under Title 35, United States Code, 119 or 365(b) of any foreign application(s) for patent or inventor's certificate, or 365(a) of any PCT international application which designated at least one country other than the United States of America, listed above and have also identified below, by check the box, any foreign application(s) for patent or inventor's certificate, or of any PCT international application having a filing date before that of the application on which priority is claimed:

Prior Foreign Application

9916400.6

(Number)

UK

(Country)

13/July/1999

(Day/Month/Year Filed)

No

Certified Copy Attached?

I hereby claim the benefit under 35 U.S.C. 119(e) of any United States provisional application(s) listed below.

Application No(s) (Day/Month/Year Filed) ☐ additional provisional application numbers are listed on a supplemental priority data sheet attached

I hereby claim the benefit under Title 35, United States, 120 of any United States application(s) or any PCT international application designating the United States of America, listed below and, insofar as the subject matter of each of the claims of this application is not disclosed in the prior United States application or PCT International application in the manner provided by the first paragraph of Title 35, United States Code, 112, I acknowledge the duty to disclose material information which is material to patentability as defined in Title 37, of Federal Regulations Code, 1.56(a) which became available between the filing date of the prior application and the national or PCT international filing date of this application:

PCT/GB00/02674

U.S. Parent Application  
or PCT Parent Number

July 11, 2000

Parent Filing Date  
(MM/DD/YYYY)

Parent Patent Number  
(If Applicable)



10031190.092402

Attorney Docket No. YOU 2 0081

POWER OF ATTORNEY: As a named inventor, I hereby appoint the following attorney(s) and/or agent(s) to prosecute this application and transact all business in the Patent and Trademark Office connected therewith.

Mark E. Bandy,	Reg. No. 35,288	Scott A. McCollister,	Reg. No. 33,961
Brian G. Bembenick,	Reg. No. 41,463	James W. McKee,	Reg. No. 26,482
John P. Cornely,	Reg. No. 41,687	Richard J. Minnich,	Reg. No. 24,175
David B. Cupar,	Reg. No. 47,510	Jay F. Moldovanyi,	Reg. No. 29,678
Joseph D. Dreher,	Reg. No. 37,123	Philip J. Moy,	Reg. No. 31,280
Matthew P. Dugan,	Reg. No. 44,663	Timothy E. Nauman,	Reg. No. 32,283
Christopher B. Fagan,	Reg. No. 22,987	Erik J. Overberger,	Reg. No. 48,556
Patrick D. Floyd,	Reg. No. 39,671	Scott C. Rand,	Reg. No. 40,359
Jude A. Fry,	Reg. No. 38,340	Patrick R. Roche,	Reg. No. 29,580
Steven M. Haas,	Reg. No. 37,841	James E. Scarbrough,	Reg. No. 47,056
Michael E. Hudzinski,	Reg. No. 34,185	Ann M. Skerry,	Reg. No. 45,655
Edward T. Kennedy,	Reg. No. 48,478	Mark S. Svat,	Reg. No. 34,261
Richard M. Klein,	Reg. No. 33,000	Anuj K. Wadhwa,	Reg. No. 50,407
Thomas E. Kocovsky,	Reg. No. 28,383	Joseph E. Walters,	Reg. No. 50,427
Sandra M. Koenig,	Reg. No. 33,722	Jason A. Worgull,	Reg. No. 48,044

## SEND CORRESPONDENCE TO:

Scott A. McCollister  
Fay, Sharpe, Fagan, Minnich & McKee, LLP  
1100 Superior Avenue, 7th Floor  
Cleveland, OH 44114-2518

DIRECT TELEPHONE CALLS TO:  
(name and telephone number)

Scott A. McCollister  
(216) 861-5582

I hereby declare that all statements made herein of my own knowledge are true and that all statements made on information and belief are believed to be true; and further that these statements were made with the knowledge that willful false statements and the like so made are punishable by fine or imprisonment, or both under 1001 of Title 18 of the United States Code and that such willful false statements may jeopardize the validity of the application or any patent issuing thereon.

100 Full name of sole or first joint inventor: Steve Yeaman

Inventor's Signature: [Signature] Date: 5/9/02Residence: UK (8 Stoneyhurst Rd, Newcastle upon Tyne) GBXCountry of Citizenship: UKPost Office Address: 8 Stoneyhurst Rd  
Newcastle upon Tyne NE3 1PA  
UK

200 Full name of second joint inventor: Peter Shepherd

Inventor's Signature: [Signature] Date: 4/9/2002Residence: 20 Beecher of Rd, London SW17 7SY, UNITED KINGDOMCountry of Citizenship: New ZealandPost Office Address: 20 Beecher of Rd  
GBX LONDON SW17 7SY

